Nitin Sahney, co-founder and CEO of PharmaCord, poses for a portrait in the pharmaceutical support company’s new headquarters and operations center in America Place, which is contained within River ...
Shares of GSK PLC GSK inched up 0.59% to £13.64 Thursday, on what proved to be an all-around positive trading session for the ...
Investor's Business Daily on MSN9h
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?Moderna stock took a beating in January after the company slashed its outlook for 2024 and 2025 and missed the mark in a ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
DelveInsight's 'Tuberculosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline tuberculosis ...
If a threshold of 10% risk of COPD was used to make spirometry referrals, the addition of the polygenic risk score correctly ...
At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...
Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA approved.
PharmaCord Founder and CEO Nitin Sahney will continue to serve on the Board of Directors and remains a significant investor in the Company. Since founding PharmaCord in 2017, Sahney has led the ...
“We are pleased to welcome Reena to Applied and are confident that her wealth of experience as a leader across quality functions will support our mission of meeting the unmet needs of patients with ...
GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...
Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback